| ²é¿´: 522 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
lionkinglk½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
Çë°ïæ·ÒëÒ»ÏÂÕâ¸ö¼ò¶ÌµÄÕªÒª£¨Ö×Áö£©
|
||
|
лл£¡£¡£¡ |
» ²ÂÄãϲ»¶
334Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085600²ÄÁÏÓ뻯¹¤×¨Ë¶329 Çóµ÷¼Á
ÒѾÓÐ21È˻ظ´
320·ÖÈ˹¤ÖÇÄܵ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸»ª¶«Àí¹¤085601²ÄÁϹ¤³Ì303·ÖÇóµ÷¼Á
ÒѾÓÐ15È˻ظ´
²ÄÁϹ¤³Ì085601£¬270Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
290Çóµ÷¼Á085701
ÒѾÓÐ17È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ4È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ26È˻ظ´
Ò»Ö¾Ô¸Äϲý´óѧ£¬085600£¬344·ÖÇóµ÷¼Á
ÒѾÓÐ12È˻ظ´
ÍÁľˮÀûר˶276·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´

RXMCDM
°æÖ÷ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 530
- Ó¦Öú: 401 (˶ʿ)
- ¹ó±ö: 1.908
- ½ð±Ò: 38947.6
- É¢½ð: 4908
- ºì»¨: 88
- ɳ·¢: 4
- Ìû×Ó: 11453
- ÔÚÏß: 1355.6Сʱ
- ³æºÅ: 2739168
- ×¢²á: 2013-10-20
- ÐÔ±ð: GG
- רҵ: Ò»°ã¹ÜÀíÀíÂÛÓëÑо¿·½·¨ÂÛ
- ¹ÜϽ: ÂÛÎÄ·Òë
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
lionkinglk: ½ð±Ò+20, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, °æÖ÷ȷʵǿº·£¬¸Ðл£¡£¡£¡ 2014-03-09 23:28:02
lionkinglk: ½ð±Ò+20, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, °æÖ÷ȷʵǿº·£¬¸Ðл£¡£¡£¡ 2014-03-09 23:28:02
| The gene unstable and mutation characteristics of the tumor cells make it easy to produce drug resistance during chemotherapy process (or later) and the recurrence and metastasis of tumor often leaded to failed treatment and threat the lives of the patients . A great number of experimental studies have confirmed that the anti-vascular therapy can reduce tumor drug-resistance, inhibite tumor occurrence and development which play a significant role of control in delaying tumor recurrence and metastasis . The effect of anti-angiogenic therapy on breast cancer is the most significant . This paper reviewed the progress of angiogenesis and anti-angiogenesis of anti-tumor therapy. |

2Â¥2014-03-09 21:22:28














»Ø¸´´ËÂ¥